Pure Bioscience (PURE) Stock Statistics & Valuation Metrics

Pure Bioscience has a market cap or net worth of $7.83M. The enterprise value is $11.01M.

Pure Bioscience has 111,886,475 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pure Bioscience’s return on equity (ROE) is 0.47 and return on invested capital (ROIC) is -1893.33%.

The current PE Ratio of Pure Bioscience is ―. Pure Bioscience’s PEG ratio is 0.00013.

In the last 12 months, Pure Bioscience had revenue of 2.20B and earned -2.40B in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -2.15M and capital expenditures 0.00, giving a free cash flow of -2.15M billion.

Pure Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Pure Bioscience upcoming earnings date is Dec 10, 2025, After Close (Confirmed).

Pure Bioscience as a current ratio of 1.12, with Debt / Equity ratio of -102.35%

In the past 12 months, Pure Bioscience has paid 0.00 in taxes.

Pure Bioscience EV to EBITDA ratio is -2.16, with an EV/FCF ratio of -2.44.

Pure Bioscience has $540.00K in cash and marketable securities with $4.90M in debt, giving a net cash position of -$4.36M billion.

Gross margin is 58.05%, with operating margin of -103.18%, and net profit margin of -108.95%.

The average price target for Pure Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―